ICON is a contract research organization ('CRO'), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. Co. specializes in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies. As of Dec 31 2008, Co. operates in 71 locations in 38 countries, providing Phase I - IV Clinical Trial Management, Drug Development Support Services, Data Management and Biostatistics and Central Laboratory and Imaging Services.
Data provided by Mergent, Inc.
Powered by Interactive Data Managed Solutions
Data provided by Thomson, Inc.
| US Record Date | US Payable Date | Net DR Amount |
|---|---|---|
| Aug 08, 2008 | Aug 12, 2008 | 0.0000 |
| Oct 13, 2006 | Oct 23, 2006 | 0.0000 |
| DR Price Date | DR Price USD | US / Non-US / Total DRs | US / Non-US / Total DR Capital Raised USD |
|---|---|---|---|
| Aug 06, 2003 | 32.25 |
3,184,744
0 3,184,744 |
102,707,994
0 102,707,994 |
| DR Symbol | ICLR |
| CUSIP | 45103T107 |
| DR Exchange | NASDAQ Stock Market |
| DR ISIN | US45103T1079 |
| Ratio | 1:1 |
| Depositary | BK (Sponsored) |
| Effective Date | May 14, 1998 |
| Underlying ISIN | IE0005711209 |
| Underlying SEDOL | 0571120 |
| Country | Ireland |
| Industry | HealthCareEquip.&Ser |
| Month |
Month End DR Close Price |
DR Trading Volume |
Avg Day DR Trading Volume |
|---|---|---|---|
Jan. 10 |
24.84 | 12,182,958 | 641,208 |
Dec. 09 |
21.73 | 6,409,826 | 291,356 |
Nov. 09 |
22.70 | 5,217,022 | 260,851 |
This DR is a Constituent of the following BNY Mellon DR Indices:
|
Related linksCustodians / BIC |
Helpful Links |